Arthneeti
FB

Fermenta Biotech Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Fermenta Biotech Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹478
Market cap₹1.4K Cr
P/E25.5
Updated24 Sept 2026
Read4 min read

Based on Fermenta Biotech Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) - 9moFY26 Revenue: INR 421.2 crore (up 25% YoY) - Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ) - 9moFY26 EBITDA: INR 97.2 Q3FY26 EBITDA: INR 28.1 crore, down 49% YoY - Q3FY26 Profit after Tax (PAT): INR 12.0 crore, down 68% YoY - Q3FY26 Revenue: INR 140.5 crore, down 11% YoY (for context) - The presentation does not explicitly state an operating margin figure nor an explicit margin outlook.

From Fermenta Biotech Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ)
  • 9moFY26 Revenue: INR 421.2 crore (up 25% YoY)
  • Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ)
  • 9moFY26 EBITDA: INR 97.2 crore (up 20% YoY)
  • Q3FY26 Profit after tax: INR 12.0 crore (down 68% YoY, down 33% QoQ)
  • 9moFY26 Profit after tax: INR 51.7 crore (up 20% YoY)
  • Human nutrition segment volumes grew 46% over 9MFY25
  • Animal nutrition segment volumes grew 52% over 9MFY25, despite an 8% decline in average realization

2 more points management made on revenue & sales performance

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly describe any specific capex amounts, capacity expansion projects, new plants, or timelines related to such developments. While it highlights: - Strategic manufacturing footprint with multiple locations (Kullu, Dahej, Thane, Pennepalli) - Innovation hub and pilot plant for process development - Collaboration with a German toll manufacturer for Vitamin D3 feed-grade powder production there are no direct mentions of planned capital expenditures, ongoing or upcoming capacity expansions, project statuses, or timelines in the provided slides. The focus is on current manufacturing capabilities and R&D facilities rather than new or expanded plant projects.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report on order book, order inflow, or pending orders. It covers financial performance, revenue mix, R&D outcomes, strategic partnerships, manufacturing capabilities, and customer diversification but does not provide specific data or commentary on: - Order backlog or order book status - New order inflow during the period - Pending or unfulfilled orders The presentation focuses on revenue growth, segment performance, cost structure, innovation initiatives, and market opportunities rather than operational order metrics.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences Ltd (Q3 FY26)

    180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Morepen Laboratories Ltd (Q3 FY26)

    488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • Jubilant Pharmova Ltd (Q3 FY26)

    2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Fermenta Biotech Ltd Q3 FY26 results?

Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) - 9moFY26 Revenue: INR 421.2 crore (up 25% YoY) - Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ) - 9moFY26 EBITDA: INR 97.2 Q3FY26 EBITDA: INR 28.1 crore, down 49% YoY - Q3FY26 Profit after Tax (PAT): INR 12.0 crore, down 68% YoY - Q3FY26 Revenue: INR 140.5 crore, down 11% YoY (for context) - The presentation does not explicitly state an operating margin figure nor an explicit margin outlook.

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fermenta Biotech Ltd planning capital expenditure?

The investor presentation does not explicitly describe any specific capex amounts, capacity expansion projects, new plants, or timelines related to such developments.

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.